Non Hodgkin Lymphoma Clinical Trial
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Summary
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
Eligibility Criteria
Inclusion Criteria:
Relapsed or Refractory B-cell Lymphoma
Measurable or Evaluable Disease
Previously treated with at least one line of rituximab or a rituximab based therapy
Patients ineligible for high dose or combination chemotherapy + stem cell transplant
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
No active or chronic infection of Hepatitis B or C and no history of HIV based on negative serology
Exclusion Criteria:
Prior chemotherapy, investigational therapy or radiotherapy within 3 weeks of study entry
Prior autologous or allogeneic stem cell transplantation within 3 months of study entry
History of severe hypersensitivity or anaphylaxis to prior rituximab
Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, brain metastasis, or psychiatric illness that would limit compliance with study requirements
Pregnant women
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Huntsville Alabama, 35805, United States
Jonesboro Arkansas, 72401, United States
Athens Georgia, 30607, United States
Macon Georgia, 31201, United States
Bethesda Maryland, 20817, United States
Morristown New Jersey, 07962, United States
New York New York, 10022, United States
Memphis Tennessee, 38120, United States
How clear is this clinincal trial information?